A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL)
A phase 3 trial of Cladribine, Cyclophosphamide and Rituximab in Leukaemia, run by Hoffmann-La Roche, completed.
Overview
A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL) is a phase 3 interventional study registered as NCT00718549 by Hoffmann-La Roche, with 128 participants recorded, started 2009-07-21 and reaching its primary completion in 2015-09-14. Interventions recorded: Cladribine, Cyclophosphamide, Rituximab. Conditions recorded: Lymphocytic Leukemia, Chronic.
Linked to the drug Cladribine because the registry names it among its interventions and Leukaemia among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialTreatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia
Shares Cladribine, Leukaemia (all types), Cyclophosphamide and the tag pipeline.
- TrialPhase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD
Shares Leukaemia (all types), Rituximab and the tag pipeline.
- TrialPalifermin for the Reduction of Oral Mucositis in Single-dose Evaluation (PROMISE)
Shares Leukaemia (all types), Cyclophosphamide and the tag pipeline.
- TrialRole of the Therapy Tailored to Risk Factors in Treating Adult Patients (≤60) With Acute Myeloid Leukemia
Shares Cladribine and the tag pipeline.
- TrialErythropoietin for Management of Anemia Caused by Chemotherapy
Shares Rituximab, Cyclophosphamide and the tag pipeline.
- TrialTreatment of Hyperuricemia With Rasburicase in Patients With Acute Lymphoblastic Leukemia or High Grade Lymphoma
Shares Leukaemia (all types) and the tag pipeline.
- TrialEfficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML)
Shares Leukaemia (all types) and the tag pipeline.
- TrialRasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2
Shares Leukaemia (all types) and the tag pipeline.